JPMorgan Chase & Co. Issues Positive Forecast for DexCom (NASDAQ:DXCM) Stock Price

DexCom (NASDAQ:DXCM) had its price objective hoisted by JPMorgan Chase & Co. from $65.00 to $82.00 in a research note released on Friday,Benzinga reports. JPMorgan Chase & Co. currently has a neutral rating on the medical device company’s stock.

A number of other equities research analysts also recently weighed in on DXCM. Raymond James Financial reissued a “strong-buy” rating and set a $94.00 price target on shares of DexCom in a research note on Friday. TD Cowen reaffirmed a “buy” rating on shares of DexCom in a report on Friday. Robert W. Baird set a $105.00 target price on shares of DexCom in a research report on Friday. Wall Street Zen downgraded DexCom from a “strong-buy” rating to a “buy” rating in a research note on Sunday, May 10th. Finally, Deutsche Bank Aktiengesellschaft initiated coverage on DexCom in a research report on Tuesday, June 23rd. They issued a “buy” rating and a $86.00 price target on the stock. Two research analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $88.12.

DexCom Stock Performance

Shares of NASDAQ:DXCM opened at $83.45 on Friday. The stock has a market capitalization of $32.20 billion, a P/E ratio of 32.98, a P/E/G ratio of 1.23 and a beta of 1.45. DexCom has a 1-year low of $54.11 and a 1-year high of $87.00. The company has a current ratio of 1.95, a quick ratio of 1.64 and a debt-to-equity ratio of 0.42. The business has a 50-day moving average price of $73.14 and a two-hundred day moving average price of $69.20.

DexCom (NASDAQ:DXCM) last released its earnings results on Thursday, July 30th. The medical device company reported $0.70 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.61 by $0.09. The company had revenue of $1.31 billion for the quarter, compared to the consensus estimate of $1.29 billion. DexCom had a net margin of 20.12% and a return on equity of 35.34%. The company’s revenue was up 13.1% compared to the same quarter last year. During the same period in the prior year, the company posted $0.48 EPS. Equities analysts predict that DexCom will post 2.57 earnings per share for the current year.

Insider Buying and Selling

In related news, EVP Michael Jon Brown sold 1,700 shares of the business’s stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $75.55, for a total value of $128,435.00. Following the completion of the transaction, the executive vice president directly owned 106,353 shares in the company, valued at approximately $8,034,969.15. The trade was a 1.57% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Kevin R. Sayer sold 26,756 shares of the business’s stock in a transaction that occurred on Monday, July 20th. The shares were sold at an average price of $76.32, for a total value of $2,042,017.92. Following the completion of the transaction, the insider owned 328,970 shares of the company’s stock, valued at $25,106,990.40. This represents a 7.52% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 98,506 shares of company stock valued at $7,205,258. 0.28% of the stock is owned by company insiders.

Institutional Trading of DexCom

Several hedge funds have recently bought and sold shares of DXCM. Tema ETFs LLC lifted its stake in DexCom by 14.2% in the second quarter. Tema ETFs LLC now owns 21,664 shares of the medical device company’s stock valued at $1,459,000 after buying an additional 2,688 shares in the last quarter. E. Ohman J or Asset Management AB increased its position in shares of DexCom by 18.9% during the second quarter. E. Ohman J or Asset Management AB now owns 113,204 shares of the medical device company’s stock worth $7,624,000 after acquiring an additional 18,012 shares in the last quarter. Paladin Wealth LLC increased its position in shares of DexCom by 17.4% during the second quarter. Paladin Wealth LLC now owns 9,338 shares of the medical device company’s stock worth $629,000 after acquiring an additional 1,386 shares in the last quarter. Arista Wealth Management LLC acquired a new stake in shares of DexCom during the second quarter worth $337,000. Finally, Sax Wealth Advisors LLC raised its holdings in shares of DexCom by 46.1% during the second quarter. Sax Wealth Advisors LLC now owns 17,001 shares of the medical device company’s stock worth $1,068,000 after acquiring an additional 5,364 shares during the period. 97.75% of the stock is currently owned by institutional investors and hedge funds.

Key Stories Impacting DexCom

Here are the key news stories impacting DexCom this week:

• Positive Sentiment: Quarterly beat and higher outlook: DexCom reported adjusted earnings of $0.70 per share versus the $0.61 consensus, while revenue rose 13.1% year over year to $1.31 billion, exceeding estimates of $1.29 billion. Management raised its 2026 revenue outlook to approximately $5.18 billion-$5.25 billion, supported by strong global demand and broader product access. Reuters article
• Positive Sentiment: Product and market expansion: Growth is being supported by the G7 15 Day continuous glucose monitor, with DexCom targeting nearly 50% U.S. conversion by year-end, as well as expanded access and continued international growth. Margin improvement also contributed to a more constructive 2026 earnings narrative. Seeking Alpha article
• Positive Sentiment: Broad analyst support: Mizuho raised its price target to $95, Royal Bank of Canada and Wells Fargo lifted targets to $90, and UBS reaffirmed a Buy rating with a $96 target. Benchmark also reaffirmed Buy, although its $82 target is below the referenced trading level. Benzinga analyst updates
• Neutral Sentiment: Mixed valuation signals: JPMorgan raised its target substantially to $82 but retained a Neutral rating, indicating that some analysts view much of the improved outlook as already reflected in the stock.
• Negative Sentiment: Insider selling: Quiver Quantitative data shows 14 insider sales and no purchases during the past six months. This is a potential cautionary signal, although it has not outweighed the earnings-driven optimism. Quiver Quantitative analysis

DexCom Company Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.